Eledon registers Phase 3 trial comparing tegoprubart with tacrolimus in kidney transplant

This week's update covers a single new trial registration for Eledon Pharmaceuticals.

• Eledon Pharmaceuticals registered a Phase 3, randomized, active-controlled, open-label study called "LEGACY" (NCT07835581) comparing tegoprubart (AT-1501) with tacrolimus in adults undergoing first kidney transplantation as part of an immunosuppressive regimen¹. The study is not yet recruiting, with an estimated start of October 2026 and primary completion in March 2029¹, and plans to enroll 620 participants¹. The trial's primary outcome is efficacy failure defined as the composite of biopsy proven acute rejection, graft loss, or death, assessed at the 12 month post-transplant mark, per the study's listed primary outcome measure.